Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.gov public full text Public Domain

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Masonic Cancer Center, University of Minnesota · 2017
ClinicalTrials.gov · Datasets · License: Public Domain · 2017
Open Source ↗
diffuse-large-b-cell-lymphomafollicular-lymphomamantle-cell-lymphomamultiple-myelomank-cellsnon-hodgkin-lymphoma
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.
Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 1262854
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive